#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myasthenia gravis Transient ischaemic attack Orthostatic hypotension Acute on chronic liver failure Systemic mastocytosis Pleural mesothelioma malignant Hypochondroplasia Basal cell naevus syndrome Anti-neutrophil cytoplasmic antibody positive vasculitis Non-renal cell carcinoma of kidney Bile acid synthesis disorder Fabry's disease Shprintzen-Goldberg syndrome Glomerulonephritis rapidly progressive Transitional cell carcinoma More trials…

    Learn about Rare Diseases

    Krabbe’s disease – Treatment Hypereosinophilic syndrome – Life with Disease Glycogen storage disease type II – Treatment Primary mediastinal large B-cell lymphoma – Diagnostics Marfan’s syndrome Gaucher’s disease type I – Treatment Myxofibrosarcoma Choroid melanoma – Basic Information Lysosomal storage disorder – Trials in Disease Familial haemophagocytic lymphohistiocytosis – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pomalidomide Lurasidone Tisotumab Vedotin Human Apotransferrin Dexmedetomidine Hydrochloride Dordaviprone ATOVAQUONE Pantothenate Sodium Ampicillin Sodium GSKVX000000039711 GSKVX000000030825 Gemcitabine Feladilimab Metyrapone Ep0042 Anhydrous Docetaxel USNOFLAST Zenocutuzumab Rbp030.2 Mercaptopurine Monohydrate More therapies…

    Learn about Your Condition

    Choroid melanoma Lumbosacral radiculopathy Vascular malformation Plasmablastic lymphoma Renal cell carcinoma Renal cancer recurrent Bacterial infection Electrocorticogram Endometrial cancer stage IV Procedural haemorrhage Lung adenocarcinoma Arrhythmia supraventricular Round cell liposarcoma Staphylococcal bacteraemia Laryngeal leukoplakia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hippokration Hospital

Hippokration Hospital

Vassilissas Sofias Avenue 114, Athens, 115 27, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +10

  • Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

    Recruiting

    3 1
    Investigated Drugs:
    • ZILEBESIRAN
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Long-term Safety Study of Vusolimogene Oderparepvec, RP2, and RP3 in Patients with Melanoma, Liver Cancer, or Advanced Solid Tumors

    Recruiting

    3 1 1
    Investigated Drugs:
    • Vusolimogene Oderparepvec
    • RP2
    • RP3
    France Germany Greece Poland Spain

  • Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7

  • Study of icotrokinra for adults with moderately to severely active Crohn’s disease

    Recruiting

    4 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7

  • A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

    Recruiting

    3 1
    Investigated Diseases:
    • Diabetes mellitus
    Investigated Drugs:
    • Teplizumab
    Belgium Czechia France Germany Greece Italy +4

  • Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis

    Recruiting

    3 1
    Investigated Drugs:
    • Risankizumab
    Belgium Germany Greece Italy Poland Spain +1

  • Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

    Recruiting

    3 1
    Investigated Diseases:
    • Cardiomyopathy
    Austria Belgium Czechia Denmark France Germany +12

  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    3 1 1
    Investigated Drugs:
    • Fexofenadine
    • Felzartamab
    • Desloratadine
    Belgium Bulgaria Croatia Czechia France Germany +5

  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiovascular disorder
    • Type 2 diabetes mellitus
    • Hypertension
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Austria Belgium Bulgaria Croatia Czechia Denmark +17
Previous Page
1 2 3 4 … 14
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!